Supplementary Materials

Conserved differences in protein sequence determine the human pathogenicity of Ebolaviruses

Authors: Morena Pappalardo†, Miguel Juliá†, Mark J. Howard, Jeremy S. Rossman*, Martin Michaelis*, Mark N. Wass*

Affiliation:

Centre for Molecular Processing and School of Biosciences, University of Kent, Canterbury, Kent CT2 7NJ, UK.

*Correspondence to: M.N.Wass@kent.ac.uk (Mark N. Wass), M.Michaelis@kent.ac.uk (Martin Michaelis), J.S.Rossman@kent.ac.uk (Jeremy S. Rossman)

† equal contribution.

Supplementary Material

Supplementary Methods - Subsampling of sequence data

The sensitivity of the SDP analysis to the number of sequences available was considered by subsampling the sequences. Sampling was performed for; only the human pathogenic group; only the Reston group; and for both groups simultaneously. Subsampling was performed using between 10%-90% of sequences in the group, increasing in 10% increments. For each percentage setting the group was sampled 50 times. Where both groups were sampled simultaneously they were done so with the same percentage of sequences i.e. at 20% sampling the SDPs were predicted each time using 20% of the human pathogenic sequences in one group and 20% of the Reston sequences in the other. For each sample s3det was run to predict SDPs using the same settings as for the full dataset. Completely conserved SDPs are also compared to those that are not completely conserved. the The total number of SDPs predicted when sampled is shown in supplementary Figure 6. When the sequences of human pathogenic Ebolaviruses were sampled, while the number of Reston sequences remained constant, we observed that the number of SDPs predicted decreased as the proportion of sequences sampled increased. We further observed that even when a very high proportion of sequences was sampled (70%-90%), that there was still some variation in the number of SDPs, indicating that there was still further information present in the excluded sequences. When the Reston virus sequences were sampled, the pattern observed varied between the proteins (Supplementary Figure 6B). For GP, L and VP30, sampling resulted in more SDPs being predicted than in the full dataset, with the number reducing as the proportion of sequences sampled increased. For NP, sampling the Reston sequences generated some samples where fewer SDPs than the total present in the full dataset were predicted and other samples where a larger number of SDPs were predicted. This is possible for SDPs that are not completely conserved in the two groups, as sampling may generate some sets of sequences where these positions appear variable and others where they are conserved. For VP35, sampling led to fewer SDPs being predicted until 90% of sequences were used. The number of SDPs in VP24 and VP40 was invariant across all samples. When sampling both groups (Supplementary Figure 6C) we found that the number of SDPs predicted very quickly converged to the number of SDPs present in the full dataset.

We then considered the number of SDPs predicted that are present in the full dataset and those that are present only in sampling (Supplementary Figure 7). When the human pathogenic sequences were sampled (Supplementary Figure 7A), we found that the vast majority of SDPs in the full data set were predicted at all sampling levels. We also found that when a small proportion of sequences were sampled,

that many new SDPs were predicted, which for some proteins (e.g. GP, NP and VP40) may be greater than the total number of SDPs present in the full dataset. This may not be too surprising given that positions that are variable in the full dataset may appear to be conserved when a small sample of sequences was taken. As the proportion of sequences sampled increased, very few new SDPs were predicted. Sampling the Reston sequences (Supplementary Figure 7B) we again found that the vast majority of SDPs present in the full dataset was present in all samples. The number of new SDPs present in samples was much smaller than for sampling of the human pathogenic sequences, which is likely to be due to the smaller number of Reston sequences, resulting in fewer samples where positions are conserved that are not conserved in the full data set. When both groups were sampled, results were very similar to that observed when the human pathogenic group was sampled (Supplementary Figure 7C).

Finally, we considered the number of SDPs in the sampling sets that are completely conserved and those that are not (Supplementary Figure 8). In conjunction with the data from Supplementary Figure 7, this shows that sampling generates new SDPs that are completely conserved (i.e. only one amino acid in each group) and also some where there is variation within one or both groups. As the proportion of sequences sampled increased these numbers quickly converged to the numbers observed in the full dataset. Some of these included SDPs which in some samples were completely conserved but as further sequences were added, variation was introduced and they were no longer completely conserved. In such cases there was a change ranking for the SDP, as when completely conserved it was ranked 1, and this ranking was reduced once the position was not completely conserved.

Supplementary Figures

Supplementary Figure 1. Phylogenetic tree of the Ebolavirus genomes and individual proteins**.** Bayesian and Maximum Likelihood phylogenetic trees are shown for the Ebolavirus genomes and each of the Ebolavirus proteins. A) genome Bayesian tree. B) Genome maximum likelihood tree, C) Bayesian tree for protein L, D)Maximum likelihood tree for protein L, E)Bayesian tree for protein GP, F)Maximum likelihood tree for protein GP, G)Bayesian tree for protein NP, H)Maximum likelihood tree for protein NP, I)Bayesian tree for protein VP24, J)Maximum likelihood tree for protein VP24, K)Bayesian tree for protein VP30, L)Maximum likelihood tree for protein VP30, M)Bayesian tree for protein VP35, N)Maximum likelihood tree for protein VP35, O)Bayesian tree for protein VP40. P)Maximum likelihood tree for protein VP40. All trees use Ebola virus as root (EBOV, Ebola virus; BDBV, Bundibugyo virus; SUDV, Sudan virus; TAFV, Taϊ Forest virus; RESTV, Reston virus).

Fig S1C.

 $\bar{\mathsf{L}}$

 GP

Fig S1H

NP

Fig S1I.

Fig S1K.

Fig S1N.

Supplementary Figure 2. Ebolavirus protein consensus sequences and SDPs. The consensus sequence for each *Ebolavirus* species is shown for each Ebolavirus protein. The row above the alignment indicates positions that are 100% conserved across all Ebolavirus sequences (black) or specificity determining positions (SDPs) that discriminate Reston viruses from the four human pathogenic *Ebolavirus* species (red); R, Reston virus; E, Ebola virus; S, Sudan virus; B, Bundibugyo virus; T, Taϊ Forest virus. A) for VP24, B) for GP, C) for VP40, D) VP35, E)VP30, F) sGP, G) NP, H)L.

A – VP24

70 80 90 100 110 120 n na mar <u> - - - - - - - - -</u> ------------m m m R KTNDFAPAWAMTRNLFPHLFQNPNSVIQSPIWALRVILAAGLQDQLLDHSLVEPLTGALG E KTNDFAPAWSMTRNLFPHLFQNPNSTIESPLWALRVILAAGIQDQLIDQSLIEPLAGALG S KVNDFAPAWAMTRNLFPHLFKNQQSEVQTPIWALRVILAAGILDQLMDHSLIEPLSGALN B KTADFAPAWSMTRNLFPHLFQNSNSTIESPLWALRVILAAGIQDQLIDQSLVEPLAGALS T KTSDFAPAWSMTRNLFPHLFQNPNSTIESPLWALRVILAAGIQDQLIDQSLIEPLAGALG

130 140 150 160 170 180 NEBERT BEREK **. . . .** n na m e e e **START** RLISDWLLTTTSTHFNLRTRSVKDQLSLRMLSLIRSNILQFINKLDALHVVNYNGLLSSIE E LISDWLLTTNTNHFNMRTQRVKEQLSLKMLSLIRSNILKFINKLDALHVVNYNGLLSSIE S LIADWLLTTSTNHFNMRTQRVKDQLSMRMLSLIRSNIINFINKLETLHVVNYKGLLSSVE B LVSDWLLTTNTNHFQMRTQHAKEQLSLKMLSLVRSNILKFISQLDALHVVNYNGLLSSIE TLIADWLLTTGTNHFQMRTQQAKEQLSLKMLSLVRSNILKFINQLDALHVVNYNGLLSSIE

190 200 210 220 230 240 _______________________ m m m <u>n din din di</u> R IGTSTHTIIITRTNMGFLVEVQEPDKSAMNSKRPGPVKFSLLHESAFKPFTRVPQSGMQS E IGTQNHTIIITRTNMGFLVELQEPDKSAMNRKKPGPAKFSLLHESTLKAFTQGSSTRMQS S IGTPSYAIIITRTNMGYLVEVQEPDKSAMDIRHPGPVKFSLLHESTLKPVATPKPSSITS BIGTRNHTIIITRTNMGFLVELQEPDKSAMNQKKPGPVKFSLLHESTFKALIKKPATKMQA T IGTKSHTIIITRTNMGFLVELQEPDKSAMNTRKPGPVKFSLLHESTLKTLAKKPATQMQA

250 R LIMEFNSLLAI E LILEFNSSLAI S LIMEFNSSLAI **BLILEFNSSLAI** TLILEFNSSLAI

70 90 110 80 100 120 ------- -- --<u>n n n n n n n </u> **REEDER** ------------- ---<u> De Barcelona de Barcelona</u> m a m R TSQLKSVGLNLEGNGIATDVPSATKRWGFRSGVPPKVVSYEAGEWAENCYNLEIKKSDGS E TNOLRSVGLNLEGNGVATDVPSVTKRWGFRSGVPPKVVNYEAGEWAENCYNLEIKKPDGS S TDQLKSVGLNLEGSGVSTDIPSATKRWGFRSGVPPKVVSYEAGEWAENCYNLEIKKPDGS B TSQLKSVGLNLEGNGVATDVPTATKRWGFRAGVPPKVVNYEAGEWAENCYNLDIKKADGS T TSQLKSVGLNLEGNGVATDVPTATKRWGFRAGVPPKVVNCEAGEWAENCYNLAIKKVDGS

130 140 150 160 170 180 <u>n e e enemene </u> HEND BERKERKERKE BER **RENER** n na m **The Contract of Contract State** R ECLPLPPDGVRGFPRCRYVHKVQGTGPCPGDLAFHKNGAFFLYDRLASTVIYRGTTFAEG E ECLPAAPDGIRGFPRCRYVHKVSGTGPCAGDFAFHKEGAFFLYDRLASTVIYRGTTFAEG S ECLPPPPDGVRGFPRCRYVHKAOGTGPCPGDYAFHKDGAFFLYDRLASTVIYRGVNFAEG BECLPEAPEGVRGFPRCRYVHKVSGTGPCPEGFAFHKEGAFFLYDRLASTIIYRSTTFSEG TECLPEAPEGVRDFPRCRYVHKVSGTGPCPGGLAFHKEGAFFLYDRLASTIIYRGTTFAEG

190 200 210 220 230 240 n manan **THE** and the state \blacksquare \blacksquare **Contract Contract** R VVAFLILSEPKKHFWKATPAHEPVNTTDDSTSYYMTLTLSYEMSNFGGEESNTLFKVDNH E VVAFLILPOAKKDFFSSHPLREPVNATEDPSSGYYSTTIRYOATGFGTNETEYLFEVDNL SVIAFLILAKPKETFLQSPPIREAVNYTENTSSYYATSYLEYEIENFGAQHSTTLFKIDNN B VVAFLILPKTKKDFFQSPPLHEPANMTTDPSSYYHTVTLNYVADNFGTNMTNFLFQVDHL TVIAFLILPKARKDFFQSPPLHEPANMTTDPSSYYHTTTINYVVDNFGTNTTEFLFQVDHL

R QLHGENLHFQILSTHTNNSSDQSPAGTVQGKISYHPPTNNSELVPTDSPPVVSVLTAGRT E KIRSEELSFTAVSNGPKNISGOSPARTSSDPETNTTNEDHKIMASENSSAMVOVHSOGRK S QLRGEELSFEALSLNETEDDDAASSRITKGRISDRATRKYSDLVPKNSPGMVPLHIPEGE B TLSSEELSVILVPRAQDPGSNQKTKVTPTSFANNQTSKNHEDLVPKDPASVVQVRDLQRE T TLSSEELSFVPVPETONOVLDTTATVSPPISAHNHAAEDHKELVSEDSTPVVOMONIKGK

620 630 640 650 610 660 <u> Bestesten de de Bestesten de Bestes de 200 e</u> **The Co** M H RRTYSLLNRKAIDFLLQRWGGTCRILGPSCCIEPHDWTKNITDEINQIKHDFIDNPLPDHG E RTFSILNRKAIDFLLQRWGGTCHILGPDCCIEPHDWTKNITDKIDQIIHDFVDKTLPDQG S RTYTILNRKAIDFLLRRWGGTCRILGPDCCIEPHDWTKNITDKINQIIHDFIDNPLPNQD BRTFSILNRKAIDFLLQRWGGTCHILGPDCCIEPHDWTKNITDKIDQIIHDFIDKPLPDQT TRTFSILNRKAIDFLLQRWGGTCHILGPDCCIEPQDWTKNITDKIDQIIHDFVDNNLPNQN

B TITHFGKTSNPLVRINRLGPGIPDHPLRLLRIGNQAFLQEFVLPPVQLPQYFTFDLTALK TTITHFGKTSNPLVRINRLGPGIPDHPLRLLRIGNOAFLOEFVLPPVOLPOYFTFDLTALK

210 220 230 240 190 200 <u> ----------- --</u> <u>n hand hendered hen</u> \mathbf{H} . \mathbf{H} **BOR & BOR B** RLITQPLPAATWTDETPAGAVNALRPGLSLHPKLRPILLPGKTGKKGHASDLTSPDKIQTI E LITQPLPAATWTDDTPTGSNGALRPGISFHPKLRPILLPNKSGKKGNSADLTSPEKIQAI SLVTQPLPAATWTDETPSNLSGALRPGLSFHPKLRPVLLPGKTGKKGHVSDLTAPDKIQTI BLITQPLPAATWTDDTPTGPTGILRPGISFHPKLRPILLPGKTGKRGSSSDLTSPDKIQAI TLITQPLPAATWTDETPAVSTGTLRPGISFHPKLRPILLPGRAGKKGSNSDLTSPDKIQAI

250 260 270 280 290 300 ------ ------**-** --<u>NA A ANALA A A ANALAH ANA ANALA</u> R MNAIPDLKIVPIDPTKNIVGIEVPELLVQRLTGKKPQPKNGQPIIPVLLPKYVGLDPISP E MTSLQDFKIVPIDPTKNIMGIEVPETLVHKLTGKKVTSKNGQPIIPVLLPKYIGLDPVAP S VNLMQDFKIVPIDPAKSIIGIEVPELLVHKLTGKKMSQKNGQPIIPVLLPKYIGLDPISP B MNFLQDLKLVPIDPAKNIMGIEVPELLVHRLTGKKITTKNGQPIIPILLPKYIGMDPISQ T MNFLQDLKIVPIDPTKNIMGIEVPELLVHRLTGKKTTTKNGQPIIPILLPKYIGLDPLSQ

70 80 90 100 110 120 <u>a masa</u> ۰. RPSSRSSTRTCTSSSQTEVNYVPLLKKVEDTLTMLVNATSRQNAAIEALENRLSTLESSLK EQQTKPNPKMRNSQTQTDPICNHSFEEVVQTLASLATVVQQQTIASESLEQRITSLENGLK SSKNPKTTRKSDKOVOTDDASSLLTEEVKAAINSVISAVRROTNAIESLEGRVTTLEASLK BKIKTPSVQTRSVQTQTDPNCNHDFAEVVKMLTSLTLVVQKQTLATESLEQRITDLEGSLK TRPKNTAPRTRNTOTOTDPVCNHNFEDVTOALTSLTNVIOKOALNLESLEORIIDLENGLK

130 140 150 160 170 180 <u>ana assessessessessesses estern der</u> RPIODMGKVISSLNRSCAEMVAKYDLLVMTTGRATSTAAAVDAYWKEHKOPPPGPALYEEN E PVYDMAKTISSLNRVCAEMVAKYDLLVMTTGRATATAAATEAYWAEHGQPPPGPSLYEES SPVQDMAKTISSLNRSCAEMVAKYDLLVMTTGRATATAAATEAYWNEHGQAPPGPSLYEDD BPVSEITKIVSALNRSCAEMVAKYDLLVMTTGRATATAAATEAYWAEHGRPPPGPSLYEED TPMYDMAKVISALNRSCAEMVAKYDLLVMTTGRATATAAATEAYWEEHGQPPPGPSLYEES

230 200 210 220 190 240 <u>.</u> \blacksquare **BR 88** <u>.</u> RALKGKIDDPNSYVPDAVQEAYKNLDSTSTLTEENFGKPYISAKDLKEIMYDHLPGFGTAF EAIRGKIESRDETVPOSVREAFNNLDSTTSLTEENFGKPDISAKDLRNIMYDHLPGFGTAF SAIKAKLKDPNGKVPESVKQAYTNLDSTSALNEENFGRPYISAKDLKEIIYDHLPGFGTAF BAIRTKIEKQGDIVPKEVQEAFRNLDSTALLTEENFGKPDISAKDLRNIMYDHLPGFGTAF TAIRGKINKOEDKVPKEVOEAFRNLDSTSSLTEENFGKPDISAKDLRDIMYDHLPGFGTAF

250 260 270 280 290 300 <u>na anasananan'ilayanananana ao amin'ny</u> 888888888 EEE **THE R** RHQLVQVICKIGKDNNLLDTIHAEFQASLADGDSPQCALIQITKRVPIFQDVPPPIIHIRS EHQLVQVICKLGKDSNSLDIIHAEFQASLAEGDSPQCALIQITKRVPIFQDAAPPVIHIRS SHQLVQVICKIGKDNNILDIIHAEFQASLAEGDSPQCALIQITKRIPAFQDASPPIVHIKS BHQLVQVICKLGKDNSSLDVIHAEFQASLAEGDSPQCALIQITKRIPIFQDAAPPVIHIRS THQLVQVICKLGKDNSALDIIHAEFQASLAEGDSPQCALIQITKRIPIFQDATPPTIHIRS

310 320 330 340 RRGDIPRACQKSLRPAPPSPKIDRGWVCLFKMQDGKTLGLKI ERGDIPRACQKSLRPVPPSPKIDRGWVCVFQLQDGKTLGLKI SRGDIPKACOKSLRPVPPSPKIDRGWVCIFOFODGKALGLKI BRGDIPKACQKSLRPVPPSPKIDRGWVCIFQLQDGKTLGLKI TRGDIPRACQKSLRPVPPSPKIDRGWVCIFQLQDGKTLGLKI

70 80 90 100 110 120 a mara a R DALIVPPAPKDICPTLKKGFLCDSKFCKKDHOLDSLNDHELLLLIARRTCGIIESNSOIT E EPLTVPPAPKDICPTLKKGFLCDSSFCKKDHQLESLTDRELLLLIARKTCGSVEQQLNIT S GTLTVPPAPKDICPTLRKGFLCDSNFCKKDHQLESLTDRELLLLIARKTCGSTDSSLNIA B DFLTVPPAPKDICPTLRKGFLCDSNFCKKDHQLESLTDRELLLLIARKTCGSLEQQLNIT T DLLTVPPAPKDVCPTLKKGFLCDSNFCKKDHOLESLTDRELLLLIARKTCGSTEOOLSIV

130 140 150 160 170 180 <u>NNH NNHH N NH</u> **INDIA BREEZER BR READER** \blacksquare **The Contract State** ■ R SPKDMRLANPTAEDFSQGNSPKLTLAVLLQIAEHWATRDLRQIEDSKLRALLTLCAVLTR E APKDSRLANPTADDFOOEEGPKITLLTLIKTAEHWARODIRTIEDSKLRALLTLCAVMTR S APKDLRLANPTADDFKQDGSPKLTLKLLVETAEFWANQNINEVDDAKLRALLTLSAVLVR BAPKDTRLANPIADDFQQKDGPKITLLTLLETAEYWSKQDIKGIDDSRLRALLTLCAVMTR TAPKDSRLANPIAEDFQQKDGPKVTLSMLIETAEYWSKQDIKNIDDSRLRALLTLCAVMTR

190 200 210 220 230 240 **RESERVE** RKFSKSQLGLLCETHLRHEGLGQDQADSVLEVYQRLHSDKGGNFEAALWQQWDRQSLIMFI E KFSKSQLSLLCETHLRREGLGQDQAEPVLEVYQRLHSDKGGSFEAALWQQWDRQSLIMFI SKFSKSQLSQLCESHLRRENLGQDQAESVLEVYQRLHSDKGGAFEAALWQQWDRQSLTMFI BKFSKSQLSLLCESHLRREGLGQDQSESVLEVYQRLHSDKGGNFEAALWQQWDRQSLIMFI TKFSKSQLSLLCESHLRREGLGQDQSESVLEVYQRLHSDKGGNFEAALWQQWDRQSLIMFI

RRKTSFLVWVIILFQRAISMPLGIVTNSTLKATEIDQLVCRDKLSSTSQLKSVGLNLEGNG E KRTSFFLWVIILFQRTFSIPLGVIHNSTLQVSDVDKLVCRDKLSSTNQLRSVGLNLEGNG SRKSSFFVWVIILFOKAFSMPLGVVTNSTLEVTEIDOLVCKDHLASTDOLKSVGLNLEGSG BRKTSFFVWVIILFHKVFPIPLGVVHNNTLOVSDIDKLVCRDKLSSTSOLKSVGLNLEGNG TRKTSFFVWVIILFHKVFSIPLGVVHNNTLQVSDIDKFVCRDKLSSTSQLKSVGLNLEGNG

130 140 150 160 170 180 HENREA BREEK ESEREESEEEE EEE EEEEEE **Contract Contract Street** RIATDVPSATKRWGFRSGVPPKVVSYEAGEWAENCYNLEIKKSDGSECLPLPPDGVRGFPR EVATDVPSVTKRWGFRSGVPPKVVNYEAGEWAENCYNLEIKKPDGSECLPAAPDGIRGFPR SVSTDIPSATKRWGFRSGVPPKVVSYEAGEWAENCYNLEIKKPDGSECLPPPPDGVRGFPR BVATDVPTATKRWGFRAGVPPKVVNYEAGEWAENCYNLDIKKADGSECLPEAPEGVRGFPR TVATDVPTATKRWGFRAGVPPKVVNCEAGEWAENCYNLAIKKVDGSECLPEAPEGVRDFPR

190 200 210 220 230 240 N B B B P N NUN UNUNU **REBERT** HERE ENERGYSEREN HER RCRYVHKVQGTGPCPGDLAFHKNGAFFLYDRLASTVIYRGTTFAEGVVAFLILSEPKKHFW ECRYVHKVSGTGPCAGDFAFHKEGAFFLYDRLASTVIYRGTTFAEGVVAFLILPOAKKDFF SCRYVHKAQGTGPCPGDYAFHKDGAFFLYDRLASTVIYRGVNFAEGVIAFLILAKPKETFL BCRYVHKVSGTGPCPEGYAFHKEGAFFLYDRLASTIIYRSTTFSEGVVAFLILPETKKDFF **TCRYVHKVSGTGPCPGGLAFHKEGAFFLYDRLASTIIYRGTTFAEGVIAFLILPKARKDFF**

320 340 350 310 330 360 **THE RE** <u>a shekara ta 1989</u> 8886 S.B RQLNETLRRNNRLSNSTGRLTWTLDPKIEPDVGEWAFWETKKTFPNNFMEKTCISKFYQPT EQLNETIYASGKRSNTTGKLIWKVNPEIDTTIGEWAFWETKKTSLEKFAVKSCLSQLYQT-SQLNDTIHLHQQLSNTTGRLIWTLDANINADIGEWAFWENKKISPNNYVEKSCLSKLYRST BQLNETIYTNGRRSNTTGTLIWKVNPTVDTGVGEWAFWENKKTSQNPFQ--S--S------TLLNETIYSDNRRSNTTGKLIWKINPTVDTSMGEWAFWENKKTHONPFO-----------

E EAGVDFOESADSFLLMLCLHHAYOGDYKLFLESGAVKYLEGHGFRFEVKKCDGVKRLEEL S EAGVDFQDNADSFLLLLCLHHAYQGDHRLFLKSDAVQYLEGHGFRFEVREKENVHRLDEL B EAGVDFQDSADSFLLMLCLHHAYQGDYKQFLESNAVKYLEGHGFRFEMKKKEGVKRLEEL T EAGVDFQESADSFLLMLCLHHAYQGDYKQFLESNAVKYLEGHGFRFEVRKKEGVKRLEEL

130 150 170 140 160 180 **The Co** \blacksquare R LPAATSGKNIRRTLAALPEEETTEANAGQFLSFASLFLPKLVVGEKACLEKVQRQIQVHA E LPAVSSGRNIKRTLAAMPEEETTEANAGQFLSFASLFLPKLVVGEKACLEKVQRQIQVHA S LPNVTGGKNLRRTLAAMPEEETTEANAGQFLSFASLFLPKLVVGEKACLEKVQRQIQVHA B LPAASSGKNIKRTLAAMPEEETTEANAGQFLSFASLFLPKLVVGEKACLEKVQRQIQVHA T LPAASSGKSIRRTLAAMPEEETTEANAGQFLSFASLFLPKLVVGEKACLEKVQRQIQVHS

190 200 210 220 230 240 R EQGLIQYPTAWQSVGHMMVIFRLMRTNFLIKYLLIHQGMHMVAGHDANDAVIANSVAQAR E EQGLIQYPTAWQSVGHMMVIFRLMRTNFLIKFLLIHQGMHMVAGHDANDAVISNSVAQAR S EQGLIQYPTSWQSVGHMMVIFRLMRTNFLIKFLLIHQGMHMVAGHDANDTVISNSVAQAR B EQGLIQYPTSWQSVGHMMVIFRLMRTNFLIKFLLIHQGMHMVAGHDANDAVIANSVAQAR T EQGLIQYPTAWQSVGHMMVIFRLMRTNFLIKFLLIHQGMHMVAGHDANDAVIANSVAQAR

310 320 330 340 350 360 R NLSGVNNLEHGLYPQLSAIALGVATAHGSTLAGVNVGEQYQQLREAATEAEKQLQQYAES E NLSGVNNLEHGLFPQLSAIALGVATAHGSTLAGVNVGEQYQQLREAATEAEKQLQQYAES S NLSGVNNLEHGLYPQLSAIALGVATAHGSTLAGVNVGEQYQQLREAATEAEKQLQQYAET B NLSGVNNLEHGLFPQLSAIALGVATAHGSTLAGVNVGEQYQQLREAATEAEKQLQKYAES T NLSGVNNLEHGLFPOLSAIALGVATAHGSTLAGVNVGEOYOOLREAATEAEKOLOKYAES

450 430 440 460 470 480 <u>---- --- -</u> <u> a ser a se</u> **BO** \blacksquare R QDDGNEIPFPGPISNNPDQDHLEDDPRDSRDTIIPNGAIDPEDGDFENYNGYHDDEVGTA E YDDDDDIPFPGPINDDDNPGHODDDPTDSODTTIPDVVVDPDDGGYGEYOSYSENGMSAP S YPDDNDIPFPGPIYDETHPNPSDDNPDDSRDTTIPGGVVDPYDDESNNYPDYEDSAEGTT BYDDDNDIPFPGPINDNENSGONDDDPTDSODTTIPDVIIDPNDGGYNNYSDYANDAASAP TYDDDNDIPFPGPINDNENSEOODDDPTDSODTTIPDIIVDPDDGRYNNYGDYPSETANAP

610 620 630 640 650 660 RASSSOODPDYTAVAPPAPVYRSAEAHEPPHKSSNEPAETSOL-NEDPDIGOSKSMOKLEE E QDRDGTSNRTPTVAPPAPVYRDHSEKKELPQDEQQDQDHI-QEARNQDSDNTQPEHSFEE S DVESVSGENNPTVAPPAPVYKDTGVDTNQQNGP-SNAVDGQGSESEALPINPEKRSALEE BSTDTTAAETKPATAPPAPVYRSISVDDSVPLEN-IPAQSNQTNNEDNVRNNAQSEQSIAE TNTETTITTTKNTTAPPAPVYRSNSEKEPLPQEK-SQKQPNQVSGSENTDNKPHSEQSVEE

730 740 8888 SSSS -- - ---R RYIYINNQQFFWPVMSPRDKFLAILQHHQ E REVTLDGQQFYWPVMNHRNKFMAILQHHQ SRYLVIDGQQFLWPVMSLQDKFLAVLQHD-BRFITMDGQQFYWPVMNHRNKFMAILQHHR T RFITMDDQQFYWPVMNHRNKFMAILQHHK

 \overline{a}

130 140 160 170 180 150 I A AN AN ANGA ANGA ANGAN П RATGAQDHLTNIATREKLKNEILNNDYVHQLFFWHDLSILARRGRLNRGNNRSTWFVHDEF ENVGAQEDCVDDHFQEKILSSIQGNEFLHQMFFWYDLAILTRRGRLNRGNSRSTWFVHDDL SQIKTQEGVITDQLKQNIRRVIHKNRYLSALFFWHDLAILTRRGRMNRGNVRSTWFVTNEV BHVGVHDDNVGKNFEPKIKALIYDNEFLQQLFYWYDLAILTRRGRLNRGNNRSTWFANDDL TRAGVHNDHVDRDFGQKIRNLICDNEVLHQMFHWYDLAILARRGRLNRGNNRSTWFASDNL

190 200 210 220 230 240 ---- --- -- - ----------- -- -**-** \blacksquare n n n n na m M M M RIDILGYGDYIFWKIPLSLLPVTIDGVPHAATDWYQPTLFKESILGHSQILSVSTAEILIM E IDILGYGDYVFWKIPISLLPLNTQGIPHAAMDWYQTSVFKEAVQGHTHIVSVSTADVLIM SVDILGYGDYIFWKIPIALLPMNTANVPHASTDWYQPNIFKEAIQGHTHIISVSTAEVLIM BIDILGYGDYIFWKIPLSLLSLNTEGIPHAAKDWYHASIFKEAVQGHTHIVSVSTADVLIM TVDILGYGDYIFWKIPLSLLPVDTQGLPHAAKDWYHESVFKEAIQGHTHIVSISTADVLIM

310 320 330 340 350 360 \mathbf{r} **The Common** a da kasa R PLCLAKIQLCSKFTERKGRFLTQMHLSVINDLRELISNRRLKDYQQEKIRDFHKILLQLQ E PLCLAKIQLCSKYTERKGRFLTQMHLAVNHTLEEITEIRALKPSQAHKIREFHRTLIRLE S PLCLAKIQLCSQYTERKGRFLTQMHLAVIQTLRELLLNRGLKKSQLSKIREFHQLLLRLR B PLCLAKIQLCSNYTERKGRFLTQMHLAVNHTLEELIEGRGLKSQQDWKMREFHRILVNLK T PLCLAKIQLCSNYTERKGRFLTQMHLAVNHTLEELTGSRELRPQQIRKVREFHQMLINLK

380 390 420 370 400 410 <mark>kana mahama kanana kana kana kana kana amin' am</mark> <u>ME NE H</u> <u>n menenena</u> m m m R LSPQQFCELFSVQKHWGHPILHSEKAIQKVKRHATILKALRPNVIFETYCVFKYNIAKHY E MTPQQLCELFSIQKHWGHPVLHSETAIQKVKKHATVLKALRPIVIFETYCVFKYSIAKHY S STPQQLCELFSIQKHWGHPVLHSEKAIQKVKNHATVLKALRPIIIFETYCVFKYSVAKHF B STPQQLCELFSVQKHWGHPVLHSEKAIQKVKKHATIIKALRPIIIFETYCVFKYSIAKHY T ATPQQLCELFSVQKHWGHPVLHSEKAIQKVKKHATVIKALRPIIIFETYCVFKYSIAKHY

490 500 510 520 530 540 ________________________________ n na R IFIKDRATAVEQTCWDAVFEPNVLGYNPPNKFSTKRVPEQFLEQEDFSIESVLNYAQELH E IFIKDRATAVERTCWDAVFEPNVLGYNPPHKFSTKRVPEQFLEQENFSIENVLSYAQKLE S IFIKDRATAVEOTCWDAVFEPNVLGYSPPYRFNTKRVPEOFLEOEDFSIESVLOYAOELR B IFIKDRATAVEKTCWDAVFEPNVLGYSPPNKFSTKRVPEQFLEQENFSIDSVLTYAQRLD T IFIKDRATAVEKTCWDAVFEPNVLGYNPPNKFATKRVPEQFLEQENFSIESVLHYAQRLE

570 580 590 550 560 600 m men R YLLPQNRNFSFSLKEKELNIGRTFGKLPYLTRNVQTLCEALLADGLAKAFPSNMMVVTER E YLLPQYRNFSFSLKEKELNVGRTFGKLPYPTRNVQTLCEALLADGLAKAFPSNMMVVTER S YLLPONRNFSFSLKEKELNVGRTFGKLPYLTRNVOTLCEALLADGLAKAFPSNMMVVTER B YLLPQYRNFSFSLKEKELNVGRAFGKLPYPTRNVQTLCEALLADGLAKAFPSNMMVVTER T YLLPEYRNFSFSLKEKELNIGRAFGKLPYPTRNVQTLCEALLADGLAKAFPSNMMVVTER

620 630 640 650 660 610 R EQKESLLHQASWHHTSDDFGENATVRGSSFVTDLEKYNLAFRYEFTAPFIEYCNHCYGVR E EQKESLLHQASWHHTSDDFGEHATVRGSSFVTDLEKYNLAFRYEFTAPFIEYCNRCYGVK S EQKESLLHQASWHHTSDDFGEHATVRGSSFVTDLEKYNLAFRYEFTAPFIKYCNQCYGVR B EQKESLLHQASWHHTSDDFGENATVRGSSFVTDLEKYNLAFRYEFTAPFIEYCNRCYGVK T EQKESLLHQASWHHTSDDFGENATVRGSSFVTDLEKYNLAFRYEFTAPFIEYCNRCYGVR

900 850 860 870 880 890 **NEWS BERNER BEER OF BEER** --------------**REE** n din sanat sa sa sa R IGTAFERAISETRHILPCRIVAAFHTYFAVRILQYHHLGFNKGIDLGQLSLSKPLDYGTI E IGTAFERSISETRHIFPCRITAAFHTFFSVRILQYHHLGFNKGFDLGQLTLGKPLDFGTI S IGTAFERSISETRHILPCRVAAAFHTYFSVRILOHHHLGFHKGSDLGOLAINKPLDFGTI BIGTAFERSISETRHVYPCRVVAAFHTFFSVRILOYHHLGFNKGTDLGOLSLSKPLDFGTI TIGTAFERSISETRHVVPCRVAAAFHTFFSVRILQYHHLGFNKGTDLGQLSLSKPLDFGTI

930 910 920 940 950 960 I AABUURKAHAANSANDU KAR<mark>a</mark>haansand ka **BRAD** . . . **.** RTLTLAVPQVLGGLSFLNPEKCFYRNFGDPVTSGLFQLRVYLEMVNMKDLFCPLISKNPGN E SLALAVPQVLGGLSFLNPEKCFYRNLGDPVTSGLFQLKTYLRMIEMDDLFLPLIAKNPGN SALSLAVPQVLGGLSFLNPEKCLYRNLGDPVTSGLFQLKHYLSMVGMSDIFHALVAKSPGN BTLALAVPQVLGGLSFLNPEKCFYRNLGDPVTSGLFQLRTYLQMINMDDLFLPLIAKNPGN TTLALAVPOVLGGLSFLNPEKCFYRNLGDPVTSGLFOLKTYLOMIHMDDLFLPLIAKNPGN

990 1000 970 980 1010 1020 RCSAIDFVLNPSGLNVPGSQDLTSFLRQIVRRSITLTARNKLINTLFHASADLEDEMVCKW E CTAIDFVLNPSGLNVPGSQDLTSFLRQIVRRTITLSAKNKLINTLFHASADFEDEMVCKW SCSAIDFVLNPGGLNVPGSQDLTSFLRQIVRRSITLSARNKLINTLFHASADLEDELVCKW BCSAIDFVLNPSGLNVPGSQDLTSFLRQIVRRTITLSAKNKLINTLFHSSADLEDEMVCKW TCSAIDFVLNPSGLNVPGSQDLTSFLRQIVRRTITLSAKNKLINTLFHSSADLEDEMVCKW

1030 1040 1050 1060 1070 1080 <u>n nan a wannan</u> п RLLSSNPVMSRFAADIFSRTPSGKRLQILGYLEGTRTLLASKIINNNSETPVLDKLRKITL E LLSSTPVMSRFAADIFSRTPSGKRLQILGYLEGTRTLLASKIINNNTETPVLDRLRKITL SLLSSTPVMSRFAADIFSRTPSGKRLQILGYLEGTRTLLASKMISNNAETPILERLRKITL BLLSSTPVMSRFAADIFSRTPSGKRLQILGYLEGTRTLLASKVINNNAETPILDRLRKITL TLLSSTPVMSRFAADIFSRTPSGKRLQILGYLEGTRTLLASKIINHNTETPILDRLRKITL

1150 1160 1170 1180 1190 1200 **THE REAL THE R THE R** n man m \blacksquare ________________ RKVKWLGQYEPCPECLNKKG--SNAYVSVAVKDQVVSAWPNTSRISWTIGSGVPYIGSRTE E KVVWLKPYEOCPOCSNAKOPGGKPFVSVAVKKHIVSAWPNASRISWTIGDGIPYIGSRTE SQTTWLKPYEQCVECSSTNN--SSPYVSVALKRNVVSAWPDASRLGWTIGDGIPYIGSRTE BNVFWLKSYEQCPKCARSRNPKGEPFVSIAIKKQVVSAWPNQSRLNWTIGDGVPYIGSRTE TNVIWLKPYEHCPKCAKSANPKGEPFVSIAIKKHVVSAWPDOSRLSWTIGDGIPYIGSRTE

1230 1210 1220 1240 1250 1260 _____________________________________ **Contract Contract Contract** <u>na kananana handan</u> RDKIGQPAIKPRCPSSALKEAIELASRLTWVTQGGSNSEQLIRPFLEARVNLSVSEVLQMT E DKIGQPAIKPKCPSAALREAIELASRLTWVTQGSSNSDLLIKPFLEARVNLSVQEILQMT S DKIGQPAIKPRCPSAALREAIELTSRLTWVTQGSANSDQLIRPFLEARVNLSVQEILQMT BDKIGQPAIKPKCPSAALREAIELTSRLTWVTQGGANSDLLVKPFVEARVNLSVQEILQMT TDKIGQPAIKPKCPSAALREAIELTSRLTWVTQGGANSDLLVKPFIEARVNLSVQEILQMT

1330 1340 1350 1360 1370 1380 **Barba** n di s n a s **TIP** <u>a sa san</u> n na RINLAVALYDIRFRNTNTSDIRHNRAHLHLTECCTKEVPAQYLTYTSALNLDLSRYRDNEL E INYAVALFDIKFRNTEATDIQYNRAHLHLTKCCTREVPAQYLTYTSTLDLDLTRYRENEL SINFAVALYDIRFRNTCTSSIQYHRAHIHLTNCCTREVPAQYLTYTTTLNLDLSKYRNNEL BINFAVALFDLRFRNTETSSIQHNRAHLHLSQCCTREVPAQYLTYTSTLSLDLTRYRENEL TINFAVALFDLRFRNVATSSIQHHRAHLHLSKCCTREVPAQYLVYTSTLPLDLTRYRDNEL

1390 1400 1410 1420 1430 1440 <u> Engel enge</u> e engelsen **RESERVE BE** \blacksquare a a s RIYDSNPLKGGLNCNLTIDSPLVKGPRLNMIEDDLLRFPHLSGWELAKTVVQSIISDNSNS EIYDNNPLKGGLNCNISFDNPFFQGKQLNIIEDDLIRLPHLSGWELAKTIMQSIISDSNNS SIYDSEPLRGGLNCNLSIDSPLMKGPRLNIIEDDLIRLPHLSGWELAKTVLQSIISDSSNS BIYDNNPLKGGLNCNLSFDNPLFKGQRLNIIEEDLIRFPHLSGWELAKTIIQSIISDSNNS TIYDDNPLRGGLNCNLSFDNPLFKGQRLNIIEEDLIRLPYLSGWELAKTVIQSIISDSNNS

1450 1460 1470 1480 1490 1500 <u>a manan</u> n na RSTDPISSGETRSFTTHFLTYPQIGLLYSFGAVLCFYLGNTILWTKKLDYEQFLYYLHNQL ESTDPISSGETRSFTTHFLTYPKIGLLYSFGAFVSYYLGNTILRTKKLTLDNFLYYLTTQI SSTDPISSGETRSFTTHFLTYPKIGLLYSFGALISFYLGNTILCTKKIGLTEFLYYLQNQI BSTDPISSGETRSFTTHFLTYPKVGLLYSFGAIVSYYLGNTIIRTKKLDLSHFMYYLTTQI TSTDPISSGETRSFTTHFLTYPKIGLLYSFGALISYYLGNTIIRTKKLTLNNFIYYLATQI

1570 1580 1590 1600 1610 1620 M M <u> E BE E BE</u> n n RQFLKSWIIDRQKTIPLWIVYPLEGQQPESINEFLHKILGLLKQGPKSIPKEVSIQNDGHL ETFVKEWIINRGTIVPLWIVYPLEGQNPTPVNNFLHQIVELLVHDSSRHQAFK--TTINDH SSFVEEWVIFRKANIPLWVIYPLEGQRPDPPGEFLNRVKSLIVGTEDDKNKGSIL--SRSG BQFVKKWIVEYRTAIPLWVVYPLEGQNPDPINSFLHQIIALLQNESP--QNNIQFQEGRNN TQFVRKWIVERKTAIPLWVIYPLEGQSPSPINSFLHHVIALLQHESS--HDHVCAAEAHSR

1630 1640 1650 1660 1670 1680 IND <mark>UNDURSERSERINGE A</mark> RDLAENNYVYNSKSTASNFFHASLAYWRSRKSRKTQDHNDFSRGDGTL----TEPVRKFSS EVHPHDNLVYTCKSTASNFFHASLAYWRSRHRNSNRKDLTRNSSTGSSTNNSDGHIKRSQE SEKCSSNLVYNCKSTASNFFHASLAYWRGRHRPKKTIGATNATTAPHI----ILPLGNSDR BQQLSDNLVYMCKSTASNFFHASLAYWRSRHKGRPKNRSTEEQTVKPRPYNNFHSVKCASN TVETFDNLVYMCKSTASNFFHASLAYWRSRSKNQDKREMTKILSLTQTEKKN--SFGYTAH

R-----NHQSDEKYYNVTCGKSPKPQERKDF--SQYRLSNNGQTMSNHRKKGKFHKWNPCK EQT--------------TRDPHDGTERSLVLQMSHEIKRTTIPQ------ENTHQGPSFQ SPPGLDLNRNNDTFIPTRIKQIVQGDSRNDRT-TTTRFPPKSRS------TPTSATEPPTK BPPSIP--KSKSGT----QGSSA-FFEKLEYD-KEIELPTASTP---AEKPKTYTKALSSR TPESTAVLGSLQTS----LAPPP-SADEATYD-RKNKVLKASRP---GKYSQNTTKAPPNQ

1750 1760 1770 1780 1790 1800 -- - -- -RMLMESQRGTVL-----------TEGDYFQNNTPPTDDVSSPHRLILPFFKLGNHNHAHD ESFLSDSACGTANPKLNFDRSRHNVKSQDHNSASKREGHQIISHRLVLPFFTLSQGTRQLT SMYEGSTTHQGK-----------LTDTHLDEDHNAKEFPSNPHRLVVPFFKLTKDGEYSI BIYHGKTPSNAAKDDSTT-----SKGCDS-----KEENAVQASHRIVLPFFTLSQNGYRTP TT-----SCRDVSPNITG-----TDGCPSANEGSNSNNNNLVSHRIVLPFFTLSHNYNERP

1810 1820 1830 1840 1850 1860 ___________________________ a annan RODAQELMNQNIKQYLHQLRSMLDTTIYCRFTGIVSSMHYKLDEVLLEYNSFDSAITLAEG ESSNESQTQDEISKYLRQLRSVIDTTVYCRFTGIVSSMHYKLDEVLWEIENFKSAVTLAEG SEPSPEESRSNIKGLLQHLRTMVDTTIYCRFTGIVSSMHYKLDEVLWEYNKFESAVTLAEG BSVKKSEYVTEITKLIROLKAIPDTTVYCRFTGVVSSMHYKLDEVLWEFDSFKTAVTLAEG TSIRKSEGTTEIVRLTRQLRAIPDTTIYCRFTGIVSSMHYKLDEVLWEFDNFKSAITLAEG

1870 1880 1890 1900 1910 1920 <u>n Annon den e</u> 88 8822 882 **8** 88 **SERVICE** \blacksquare n di s REGSGALLLLQKYSTRLLFLNTLATEHSIESEVVSGFSTPRMLLPIMQKVHEGQVTVILNN EEGAGALLLIQKYQVKTLFFNTLATESSIESEIVSGMTTPRMLLPVMSKFHNDQIEIILNN SEGSGALLLIQKYGVKKLFLNTLATEHSIESEVISGYTTPRMLLSIMPKTHRGELEVILNN BEGSGALLLLQKYKVRTIFFNTLATEHSIEAEIVSGTTTPRMLLPVMAKLHDDQINVILNN TEGSGALLLLQKYKVETLFFNTLATEHSIEAEIISGITTPRMLLPIMSRFHGGQIKVTLNN

1990 2000 2010 2020 2030 2040 <u>n n n n n n</u> <u> - - - - - - - - - - </u> **Contract Contract** _____________ RLKVVVLKVFLSDIEGILWINDYLAPLFGAGYLIKPITSSARSSEWYLCLSNLISTNRRSA E LKAVVLKVFLSDTEGMLWLNDNLAPFFATGYLIKPITSSARSSEWYLCLTNFLSTTRKMP SLKVVILKVFLSDLDGMCWINNYLAPMFGSGYLIKPITSSAKSSEWYLCLSNLLSTLRTTQ BLKIVIIKVFLSDIDGLLWLNDHLAPLFGSGYLIKPITSSPKSSEWYLCLSNFLSASRRRP TLKVVVLKVFLSDIDGILWLNDNLTPLFGLGYLIKPITSSPKSSEWYLCLSNLLSTSRRLP

2090 2050 2060 2070 2080 2100 ___ __ _________ a a shekara M N RHQTHKACLGVIRDALQAQVQRGVYWLSHIAQYATKNLHCEYIGLGFPSLEKVLYHRYNLV E HQNHLSCKQVILTALQLQIQRSPYWLSHLTQYADCDLHLSYIRLGFPSLEKVLYHRYNLV SHQTQANCLHVVQCALQQQVQRGSYWLSHLTKYTTSRLHNSYIAFGFPSLEKVLYHRYNLV BHQGHATCMQVIQTALRLQVQRSSYWLSHLVQYADINLHLSYVNLGFPSLEKVLYHRYNLV THQSHTTCMHVIQTALQLQIQRSSYWLSHLVQYANHNLHLDYINLGFPSLERVLYHRYNLV

2110 2120 2130 2140 2150 2160 **THE R CONTRACTOR** RDTGLGPLSSVIRHLTNLQAEIRDLVLDYNLMRESRTQTYHFIKTAKGRITKLVNDFLKFS E DSKRGPLVSVTQHLAHLRAEIRELTNDYNQQRQSRTQTYHFIRTAKGRITKLVNDYLKFF S DSRNGPLVSITRHLALLOTEIRELVTDYNOLROSRTOTYHFIKTSKGRITKLVNDYLRFE BDSRKGPLVSILYHLTHLQAEIRELVCDYNQQRQSRTQTYHFIKTTKGRITKLVNDYLKFY TDSQKGPLTSIVQHLAHLQTEIRELVNDYNQQRQSRTQTYHFIKTIKGRITKLVNDYLKFF

2230 \blacksquare **REAL** R RLTGLMRFYPEGLIYSNHT ERLTGLLSLFPDGLYRFD--SRLTSLVNMFPEGFRSSSV-BRLTGFLGLYPNGINT----TRLTGLLSLCPNGFFR----

Supplementary Figure 3. Solvent Accessible surface area for Ebolavirus SDPs. Histograms showing the Solvent Accessible surface area in square ångstroms of SDPs. Values are calculated for the Ebola virus structure and residues.

Supplementary Figure 4. GP SDPs. A) Heatmap of intra- and inter-species GP sequence identity (EBOV, Ebola virus; BDBV, Bundibugyo virus; SUDV, Sudan virus; TAFV, Taϊ Forest virus; RESTV, Reston virus). B) Monomeric representation of GP with GP1 (grey) and GP2 (blue). D) EBOV GP trimer (PDB code: 3CSY) with SDPs colored red. The three GP1 chains are colored grey. The three GP2 chains are colored blue, green and yellow. C) Electrostatics surfaces for the EBOV structure (3CSY) and a model of a RESTV GP trimer based on 3CSY.

Supplementary Figure 5. GP SDPs are located outside the putative NPC1 binding site. GP SDPS are shown in red. The putative NPC1 binding site is shown in cyan.

Supplementary Figure 6. SDP prediction with subsampling of Ebolavirus sequences. The two groups of sequences 'human pathogenic' and Reston ('non human pathogenic') were sampled and SDP predictions made (see materials and methods). The boxplots show the distributions of the number of SDPs predicted in the simulations where A) only human pathogenic sequences were sampled, B) only Reston sequences were sampled and C) both sets were sampled. Sampling was performed for samples consisting of between 10%-90% of sequences (x axis). Red lines indicate the number of SDPs predicted in the full dataset without sampling. Note the scale of the Y-axis varies between each plot.

A. **Human pathogenic sequence sampled.**

B. **Reston Sequences Sampled**

C. **Both groups sampled**

Supplementary Figure 7. Change in SDP prediction with subsampling of Ebolavirus sequences. The two groups of sequences 'human pathogenic' and and Reston ('non human pathogenic') were sampled and SDP predictions made (see materials and methods). The boxplots show the number of SDPs predicted in each sampling that are also in the full dataset (red) and new SDPs that are predicted only in subsamples (blue). The black horizontal line indicates the number of SDPs predicted using the full dataset. Subsampling performed for A) only human pathogenic sequences were sampled, B) only Reston sequences were sampled and c) both sets were sampled.

1

1

A. **Human pathogenic sequence sampled.**

% sampled

B. Reston Sequences Sampled

VP35

 $\overline{}$ п

10 20 30 40 50 60 70 80 90 % sampled

□ □ \cdot ≛ **Var1**

1 2

1

0

7

5

10

Number of SDPs

Number of SDPs

15

10 20 30 40 50 60 70 80 90 % sampled

Ē

Ξ

 $\stackrel{\bullet}{_{\bullet}}$

≗

0

 $\ddot{\bullet}$

¢

C. Both groups sampled

Supplementary Figure 8. Analysis of completely conserved SDP with subsampling of Ebolavirus sequences. The two groups of sequences 'human pathogenic' and and Reston ('non human pathogenic') were sampled and SDP predictions made (see materials and methods). The boxplots show the number of SDPs predicted in each sampling that are are completely conserved (red) and not completely conserved (blue). The red horizontal line indicates the number of completely conserved SDPs present in the full dataset and the blue line represents the equivalent for SDPs that are not completely conserved. Subsampling performed for A) only human pathogenic sequences were sampled, B) only Reston sequences were sampled and c) both sets were sampled.

2

1

 $0.0 +$

10 20 30 40 50 60 70 80 90 % sampled

B. Reston Sequences Sampled

Supplementary Tables

Supplementary Table 1. Variation within the Ebolavirus genomes. The number of positions in the Ebolavirus protein multiple sequence alignments that are completely conserved and those that have variation are shown.

Supplementary Table 2. VP24 SDPs. The position in the multiple sequence alignment, the amino acid position, and amino acid present in each of the species is shown. The BLOSUM62 score represents how frequently such amino acid changes are observed in nature. SASA is the solvent accessible surface area, which is only available for SDPs that could be mapped to protein structure. SASA was calculated using the protein structure with PDB code 4M0Q. RESTV, Reston virus; EBOV, Ebola virus; B, Bundibugyo virus; SUDV, Sudan virus; TAFV, Taϊ Forest virus. The s3det column shows the ranking of the SDPs by s3det.

Supplementary Table 3. VP30 SDPs. The position in the multiple sequence alignment, the amino acid position, and amino acid present in each of the species is shown. The BLOSUM62 score represents how frequently such amino acid changes are observed in nature. SASA is the solvent accessible surface area, which is only available for SDPs that could be mapped to protein structure. SASA was calculated using the protein structure with PDB code 2I8B. RESTV, Reston virus; EBOV, Ebola virus; B, Bundibugyo virus; SUDV, Sudan virus; TAFV, Taϊ Forest virus. The s3det column shows the ranking of the SDPs by s3det.

Supplementary Table 4. VP35 SDPs. The position in the multiple sequence alignment, the amino acid position, and amino acid present in each of the species is shown. The BLOSUM62 score represents how frequently such amino acid changes are observed in nature. SASA is the solvent accessible surface area, which is only available for SDPs that could be mapped to protein structure. SASA was calculated using the protein structure with PDB code 4IBB. RESTV, Reston virus; EBOV, Ebola virus; B, Bundibugyo virus; SUDV, Sudan virus; TAFV, Taϊ Forest virus. The s3det rank column shows the ranking of the SDPs by s3det. The s3det column shows the ranking of the SDPs by s3det.

Supplementary Table 5. VP40 SDPs. The position in the multiple sequence alignment, the amino acid position, and amino acid present in each of the species is shown. The BLOSUM62 score represents how frequently such amino acid changes are observed in nature. SASA is the solvent accessible surface area, which is only available for SDPs that could be mapped to protein structure. SASA was calculated using the protein structure with PDB code 1ES6. RESTV, Reston virus; EBOV, Ebola virus; B, Bundibugyo virus; SUDV, Sudan virus; TAFV, Taϊ Forest virus. The s3det column shows the ranking of the SDPs by s3det.

Supplementary Table 6. NP SDPs. The position in the multiple sequence alignment, the amino acid position, and amino acid present in each of the species is shown. The BLOSUM62 score represents how frequently such amino acid changes are observed in nature. SASA is the solvent accessible surface area, which is only available for SDPs that could be mapped to protein structure. SASA was calculated using the protein structure with PDB code 4QB0 for the C terminal and 4YPI for the N terminal regions. RESTV, Reston virus; EBOV, Ebola virus; B, Bundibugyo virus; SUDV, Sudan virus; TAFV, Taϊ Forest virus. The s3det rank column shows the ranking of the SDPs by s3det. The s3det column shows the ranking of the SDPs by s3det.

Supplementary Table 7. GP SDPs. The position in the multiple sequence alignment, the amino acid position, and amino acid present in each of the species is shown. The BLOSUM62 score represents how frequently such amino acid changes are observed in nature. SASA is the solvent accessible surface area, which is only available for SDPs that could be mapped to protein structure. SASA was calculated using the protein structure with PDB code 3CSY. RESTV, Reston virus; EBOV, Ebola virus; B, Bundibugyo virus; SUDV, Sudan virus; TAFV, Taϊ Forest virus. The s3det rank column shows the ranking of the SDPs by s3det. The s3det column shows the ranking of the SDPs by s3det.

Supplementary Table 8. sGP SDPs. The position in the multiple sequence alignment, the amino acid position, and amino acid present in each of the species is shown. The BLOSUM62 score represents how frequently such amino acid changes are observed in nature. SASA is the solvent accessible surface area, which is only available for SDPs that could be mapped to protein structure. SASA was calculated using the Phyre2 structural model that used template structure 3s88I. RESTV, Reston virus; EBOV, Ebola virus; B, Bundibugyo virus; SUDV, Sudan virus; TAFV, Taϊ Forest virus. The s3det rank column shows the ranking of the SDPs by s3det. The s3det column shows the ranking of the SDPs by s3det.

Supplementary Table 9. L SDPs. The position in the multiple sequence alignment, the amino acid position, and amino acid present in each of the species is shown. The BLOSUM62 score represents how frequently such amino acid changes are observed in nature. SASA is the solvent accessible surface area, which is only available for SDPs that could be mapped to protein structure. SASA was calculated using the Phyre2 structural model which used template 4n48A ("cap-specific mrna ("cap-specific mrna (nucleoside-2'-o-)-methyltransferase 1 protein in2 complex with capped rna fragment"). RESTV, Reston virus; EBOV, Ebola virus; B, Bundibugyo virus; SUDV, Sudan virus; TAFV, Taϊ Forest virus. The s3det rank column shows the ranking of the SDPs by s3det. The s3det column shows the ranking of the SDPs by s3det.

Supplementary Table 10. SDPs that coincide with known mutagenesis data. Functional data extracted from UniProt unless stated. Res, residue; EBOV, Ebola virus; RESTV, Reston virus *Data from Bornholdt et al.,³⁵

Supplementary Table 11. Protein structures available for Ebolavirus Proteins. EBOV, Ebola virus; RESTV, Reston virus

Supplementary Table 12. Structural analysis of GP SDPs. Details of the structural analysis are included with an assessment of whether the amino acid change is likely to have an effect on the protein. Four categories are used for the effect column unlikely (the change seems unlikely to alter the structure/function), unclear (the change could be functional but there is limited evidence), possible (more confident that there is an effect than the unclear group) and probably (highly confident that the change will have a structural/functional effect).

Supplementary Table 13. Structural analysis of NP SDPs. Details of the structural analysis are included

with an assessment of whether the amino acid change is likely to have an effect on the protein. Four categories are used for the effect column unlikely (the change seems unlikely to alter the structure/function), unclear (the change could be functional but there is limited evidence), possible (more confident that there is an effect than the unclear group) and probably (highly confident that the change will have a structural/functional effect).

Supplementary Table 14. Structural analysis of VP35 SDPs. Details of the structural analysis are included with an assessment of whether the amino acid change is likely to have an effect on the protein. Four categories are used for the effect column unlikely (the change seems unlikely to alter the structure/function), unclear (the change could be functional but there is limited evidence), possible (more confident that there is an effect than the unclear group) and probably (highly confident that the change will have a structural/functional effect).

Supplementary Table 15. Structural analysis of VP30 SDPs. Details of the structural analysis are included with an assessment of whether the amino acid change is likely to have an effect on the protein. Four categories are used for the effect column unlikely (the change seems unlikely to alter the structure/function), unclear (the change could be functional but there is limited evidence), possible (more confident that there is an effect than the unclear group) and probably (highly confident that the change will have a structural/functional effect).

Supplementary Table 16. Structural analysis of VP40 SDPs. Details of the structural analysis are included with an assessment of whether the amino acid change is likely to have an effect on the protein. Four categories are used for the effect column unlikely (the change seems unlikely to alter the structure/function), unclear (the change could be functional but there is limited evidence), possible (more confident that there is an effect than the unclear group) and probably (highly confident that the change will have a structural/functional effect). Analysis is based on the VP40 dimer structure unless otherwise stated.

Supplementary Table 17. Structural analysis of VP24 SDPs. Details of the structural analysis are included with an assessment of whether the amino acid change is likely to have an effect on the protein. Four categories are used for the effect column unlikely (the change seems unlikely to alter the structure/function), unclear (the change could be functional but there is limited evidence), possible (more confident that there is an effect than the unclear group) and probably (highly confident that the change will have a structural/functional effect).

Supplementary Table 18. Residues in VP24 previously identified to differ between Reston viruses and Ebola viruses and/or Sudan viruses. Zhang et al., identified five regions that differed between Reston viruses and Ebola viruses and/or Sudan viruses⁷. The five regions are listed along with conservation information i.e. whether the position is an SDP, varies in a species specific manner (i.e. not an SDP, but a different residue is conserved in each of the different species) or otherwise conserved. Region one is part of the KPNA5 (karyopherin α5) binding site and region two is thought to be part of the STAT1 binding site⁷.

Supplementary Table 19. VP24 Mutations occurring in adaption of Ebola virus to rodent species. The location of the mutation and how it may alter structure and function is listed with details of proximity to SDPs. *indicates that after passage one the predominant amino acid at that position was the wild type 44 . In the Dowall et al. 45 , study L26F is the only mutation where the mutation is predominantly maintained in in all passages. Separate experimental evidence suggests that the L26F mutation along results in pathogenicity in guinea pigs³⁷.

Supplementary Table 20. Information on the 196 complete *Ebolavirus* **genomes.** Genomes were downloaded from Virus Pathogen Resource, VIPR (http://www.viprbrc.org/brc/home.spg?decorator=vipr) .

Supplementary Table 21. Effective number of independent sequences in the dataset. The effective number of independent sequences present in the multiple sequence alignments for each of the Ebolavirus proteins is shown. Values were calculated using hmmer (see material and methods).